Life Sciences VCs Leave Morgenthaler, ATV To Form New Fund
This article was originally published in The Pink Sheet Daily
The two teams will exit their hybrid funds and raise capital for a new vehicle intended solely for life sciences startups.
You may also be interested in...
A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.
Plus the latest financing news from Denmark’s Symphogen, ScioDerm, Esperion Therapeutics and Intrexon.
A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”